Unique combination of FibroMeterTM blood test with ...

Unique combination of FibroMeterTM blood test with

FibroScan? result for optimal liver fibrosis assessment

First integrated diagnostic score meeting requirements of international

guidelines: combination of liver stiffness measurement (FibroScan?)

and blood markers (FibroMeterTM)

Best algorithm to identify and manage patient from early

to advanced fibrosis: maximized & consistent AUROCs performance

across fibrosis stages (F2, F3, F4)

Optimal solution to confirm fibrosis stage assessment

without liver biopsy: improved balance of Positive Predicitve

Value and Negative Predictive Value

1.0

F4

0.8

F3

0.6

F2

Liver stiffness

0.4

F1

0.2

PLT

F0

0.0

+

GGT

AST

A2M

PI

One SCORE, one CLASSIFICATION:

optimum performance and easy to read

F0

F1

F2

F3

F4

Classification F3

Score 0,81

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

FibroMeter VCTE? is in vitro diagnostic medical device as defined by Directive 98/79/EC. These scores, based on blood parameters, are useful tools for diagnosing and measuring the extent of liver fibrosis in patients with chronic

liver disease of viral (including HIV co-infection), alcohol-related, or metabolic origin. Products in the FibroScan? range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a

medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. FibroScan? examinations must be performed only by an operator who is certified by the manufacturer or its approved local

representative. You are expressly recommended to carefully read the guide and the instructions given in the User Manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. This marketing tool

is not intended for circulation in the United States. FibroScan? and FibroMeter VCTE? are registered trademarks of Echosens?.

? Copyright Echosens ¨C All rights reserved - FibroMeter VCTE? leaflet EN 0319.

Unique combination of FibroMeterTM blood test with

FibroScan? result for optimal liver fibrosis assessment

Maximized & consistent performance across fibrosis stages (F2, F3, F4)

Performances in NAFLD patients (N = 225)

1

APRI

0,9

FIB4

0,8

FibroTest

0,7

FibroScan? LSM (alone)

0,6

FibroMeterTM (alone)

0,5

F¡Ý2

F¡Ý3

Fibrosis stages

Fibrometer VCTETM

F¡Ý4

Ducancelle, J Clin Gastroenterology, 2017

Optimal balance of diagnostic PPV & NPV

FibroScan? alone (LSM) and FibroMeter VCTE (FibroScan? + FibroMeterTM) negative and positive predictive value (N=215)

100%

90%

80%

99%

92%

FibroScan? LSM (alone)

89%

84%

82%

83%

Fibrometer VCTETM

71%

70%

61%

60%

50%

40%

30%

20%

10%

0%

NPV

PPV

F¡Ý2

NPV

Loong, J. Gastroenterol, 2016

PPV

F¡Ü3

First-in-class clinical performance:

FibroMeter VCTETM outperforms other fibrosis tests

Performances in NAFLD patients for advanced fibrosis F¡Ý3 (N = 410)

0,86

0,77

0,69

APRI

0,71

NFSA

0,80

0,80

0,81

0,81

ELF

FibroMeter?

2G (alone)

FibroScan? LSM (alone)

0,74

FIB4

HEPASCORE

FibroMeter? (alone)

AUROcs of tests for advanced fibrosis by kleiner F.

Cal¨¨s, poster #SAT279 ILC (EASL) 2019

FibroMeter VCTE?

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download